Clodronic acid | CAS# 10596-23-3 | bone resorption inhibitor

MedKoo Cat#: 413106 | Name: Clodronic acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clodronic acid or clodronate disodium is a bisphosphonate and a bone resorption inhibitor and antihypercalcemic agent. It is used in experimental medicine to selectively deplete for macrophages. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.

Chemical Structure

Clodronic acid

CAS#10596-23-3

Theoretical Analysis

MedKoo Cat#: 413106

Name: Clodronic acid

CAS#: 10596-23-3

Chemical Formula: CH4Cl2O6P2

Exact Mass: 243.8860

Molecular Weight: 244.88

Elemental Analysis: C, 4.90; H, 1.65; Cl, 28.95; O, 39.20; P, 25.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

22560-50-5 (sodium ) 10596-23-3 (free acid) 88416-50-6 (hydrate)

Synonym

Clodronic acid; BRN1876367; BRN-1876367; BRN 1876367

IUPAC/Chemical Name

(dichloromethylene)bis(phosphonic acid)

InChi Key

ACSIXWWBWUQEHA-UHFFFAOYSA-N

InChi Code

InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)

SMILES Code

OP(O)(C(Cl)(P(O)(O)=O)Cl)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Two early observations about the first generation bisphosphonate, clodronate, suggested that it would likely have clinical utility; specifically, it was a more potent anti-resorptive but a less potent inhibitor of mineralisation than its predecessor etidronate. The known mechanism of action differs from that of the later nitrogen-containing bisphosphonates, as clodronate is metabolised intracellularly to a toxic analog of adenosine triphosphate, AppCCl2p, which causes mitochondrial dysfunction, impaired cellular energy metabolism and osteoclast apoptosis. For pre-clinical studies in a variety of disease models, liposomal clodronate has become the agent of choice for macrophage depletion, for example in a recent study to enhance haematopoietic chimerism and donor-specific skin allograft tolerance in a mouse model. For clinical use, clodronate was developed in oral and injectable formulations; while poorly absorbed from the gastro-intestinal tract, its absorption at 1-3% of the administered dose is approximately three-fold higher than for nitrogen-containing bisphosphonates. Following an early setback due to an erroneous association with toxic adverse events, a number of successful clinical studies have established clodronate, predominantly in its oral formulations, as a highly successful treatment in Paget's disease, hypercalcaemia (benign and malignant), multiple myeloma, and early or metastatic breast cancer. Novel uses in other disease areas, including veterinary use, continue to be explored. (copied from https://pubmed.ncbi.nlm.nih.gov/33127577/)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 244.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: McCloskey E, Paterson AH, Powles T, Kanis JA. Clodronate. Bone. 2021 Feb;143:115715. doi: 10.1016/j.bone.2020.115715. Epub 2020 Oct 27. PMID: 33127577. 2: Culemann S, Knab K, Euler M, Wegner A, Garibagaoglu H, Ackermann J, Fischer K, Kienhöfer D, Crainiciuc G, Hahn J, Grüneboom A, Nimmerjahn F, Uderhardt S, Hidalgo A, Schett G, Hoffmann MH, Krönke G. Stunning of neutrophils accounts for the anti-inflammatory effects of clodronate liposomes. J Exp Med. 2023 Jun 5;220(6):e20220525. doi: 10.1084/jem.20220525. Epub 2023 Mar 28. PMID: 36976180; PMCID: PMC10067541. 3: Moriyama Y, Nomura M. Clodronate: A Vesicular ATP Release Blocker. Trends Pharmacol Sci. 2018 Jan;39(1):13-23. doi: 10.1016/j.tips.2017.10.007. Epub 2017 Nov 13. PMID: 29146440. 4: Franzosi MG, Devoto MA. Clodronato [Clodronate]. Medicina (Firenze). 1988 Jan-Mar;8(1):105-9. Italian. PMID: 2976107. 5: Saviola G, Abdi-Ali L, Comini L, Dalle-Carbonare LG. Use of clodronate in the management of osteoarthritis: an update. J Biol Regul Homeost Agents. 2019 September-October,;33(5):1315-1320. doi: 10.23812/19-58-A. PMID: 31591875. 6: Mass E. The stunning clodronate. J Exp Med. 2023 Jun 5;220(6):e20230339. doi: 10.1084/jem.20230339. Epub 2023 Mar 28. PMID: 36976179; PMCID: PMC10067525. 7: Frediani B, Giusti A, Bianchi G, Dalle Carbonare L, Malavolta N, Cantarini L, Saviola G, Molfetta L. Clodronate in the management of different musculoskeletal conditions. Minerva Med. 2018 Aug;109(4):300-325. doi: 10.23736/S0026-4806.18.05688-4. PMID: 29947493. 8: Moretti A, Paoletta M, Liguori S, Ilardi W, Snichelotto F, Toro G, Gimigliano F, Iolascon G. The Rationale for the Intra-Articular Administration of Clodronate in Osteoarthritis. Int J Mol Sci. 2021 Mar 7;22(5):2693. doi: 10.3390/ijms22052693. PMID: 33799992; PMCID: PMC7962069. 9: Saviola G, Abdi-Ali L, Povino MR. CLODRONATE: OLD DRUG, NEW USES. J Biol Regul Homeost Agents. 2015 Jul-Sep;29(3):719-22. PMID: 26403413. 10: Kanis JA, McCloskey EV, Beneton MN. Clodronate and osteoporosis. Maturitas. 1996 May;23 Suppl:S81-6. doi: 10.1016/0378-5122(96)01018-3. PMID: 8865146. 11: Markell R, Saviola G, Barker EA, Conway JD, Dujardin C. What Do We Know About Clodronate Now? A Medical and Veterinary Perspective. J Equine Vet Sci. 2020 May;88:102874. doi: 10.1016/j.jevs.2019.102874. Epub 2019 Nov 23. PMID: 32303308. 12: Koike T, Miura K, Hatta Y, Nakamura H, Hirabayashi Y, Yuda M, Harada T, Hirai S, Tsuboi I, Aizawa S. Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis. Ann Hematol. 2023 Dec;102(12):3311-3323. doi: 10.1007/s00277-023-05425-w. Epub 2023 Sep 1. PMID: 37656190. 13: Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994 Jun;47(6):945-82. doi: 10.2165/00003495-199447060-00007. PMID: 7521833. 14: van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res. 2002 Feb-May;12(1-2):81-94. doi: 10.1081/lpr-120004780. PMID: 12604042. 15: Dando TM, Wiseman LR. Clodronate : a review of its use in the prevention of bone metastases and the management of skeletal complications associated with bone metastases in patients with breast cancer. Drugs Aging. 2004;21(14):949-62. doi: 10.2165/00002512-200421140-00005. PMID: 15554753. 16: Hurst M, Noble S. Clodronate: a review of its use in breast cancer. Drugs Aging. 1999 Aug;15(2):143-67. doi: 10.2165/00002512-199915020-00007. PMID: 10495073. 17: Martos-Fernández M, Saez-Barba M, López-López J, Estrugo-Devesa A, Balibrea- Del-Castillo JM, Bescós-Atín C. Pentoxifylline, tocopherol, and clodronate for the treatment of mandibular osteoradionecrosis: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):431-439. doi: 10.1016/j.oooo.2018.02.004. Epub 2018 Feb 14. PMID: 29550081. 18: Arthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, Hendrickson JE, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion. 2022 May;62(5):948-953. doi: 10.1111/trf.16872. Epub 2022 Apr 26. PMID: 35470900; PMCID: PMC9491148. 19: Ghinoi V, Brandi ML. Clodronate: mechanisms of action on bone remodelling and clinical use in osteometabolic disorders. Expert Opin Pharmacother. 2002 Nov;3(11):1643-56. doi: 10.1517/14656566.3.11.1643. PMID: 12437497. 20: Knych HK, Finno CJ, Katzman S, Ryan D, McKemie DS, Kass PH, Arthur RM. Clodronate detection and effects on markers of bone resorption are prolonged following a single administration to horses. Equine Vet J. 2023 Jul;55(4):696-706. doi: 10.1111/evj.13866. Epub 2022 Aug 23. PMID: 35871470.